uploads/2017/05/Chart-008-Neuro-1.jpg

Performance of Eli Lilly’s Neuroscience Products in 1Q17

By

Updated

Neuroscience products

Eli Lilly & Co.’s (LLY) neuroscience products portfolio includes the drugs Cymbalta, Strattera, and Zyprexa. The chart below shows revenues for its three key neuroscience products—Cymbalta, Strattera, and Zyprexa—since 1Q15.

Article continues below advertisement

Cymbalta

Cymbalta, an antidepressant, reported a 12% decline in its 1Q17 revenues to $174.6 million, compared to ~$198.7 million in 1Q16. The drug reported lower sales outside the US markets, specifically Europe and Canada, due to the loss of exclusivity

Cymbalta reported a 20% decline in revenues to $140.5 million from international markets, partially offset by 46% growth in the US market to $34.1 million.

Strattera

Strattera, a drug for the treatment of attention-deficit hyperactivity disorder (or ADHD), reported 4% growth in its 1Q17 revenues to $196.2 million, compared to $188.1 million for 1Q16. This growth was driven by strong performance in its US and international markets.

Zyprexa

Zyprexa, an antipsychotic drug, reported a 31% decline in revenues to $147.5 million in 1Q17, compared to $212.8 million in 1Q16. The decline was due to the exposure to generic competition in the US and its international markets.

For broad-based exposure to the industry, investors can consider the Vanguard Healthcare ETF (VHT), which holds 2.4% of its total assets in Eli Lilly. VHT also holds 10.0% of its total assets in Johnson & Johnson (JNJ), 2.9% of its total assets in Celgene (CELG), 2.2% of its total assets in Abbott Laboratories (ABT), and 1.7% of its total assets in Biogen (BIIB).

Advertisement

More From Market Realist